(Press-News.org) Use of folic acid supplements appears to lower blood levels of the amino acid homocysteine—theorized to be a risk factor for heart and blood vessel disease—but does not appear to be associated with reduced rates of cardiovascular events, cancer or death over a five-year period, according to a meta-analysis of previously published studies in the October 11 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.
"Elevated plasma total homocysteine [an amino acid created by the body, usually as a byproduct of eating meat] has been suggested as a potentially modifiable risk factor for coronary heart disease, stroke and other occlusive vascular conditions," the authors write as background information in the article. High rates of cardiovascular disease in children with homocystinuria—a rare genetic condition causing extreme elevations in homocysteine levels—led researchers to hypothesize that moderate increases in blood homocysteine levels may increase cardiovascular disease risk in the general population.
Supplementation with B vitamins, and in particular folic acid, lowers blood homocysteine levels and reduces cardiovascular disease risk among individuals with homocystinuria. Several large clinical trials conducted in patients without the condition have been inconclusive. "Consequently, a collaboration between their investigators was established in 2004 to conduct a meta-analysis based on individual participant data from all large randomized trials of folic acid–based B-vitamin supplementation intended to lower plasma homocysteine levels for the prevention of cardiovascular disease," the authors write.
Robert Clarke, F.R.C.P., University of Oxford, England, and colleagues in the B-Vitamin Treatment Trialists' Collaboration report the results of the meta-analysis of all eight trials completed by the end of 2009. Of a total of 37,485 participants, 18,723 were assigned to take folic acid in doses ranging from 0.8 milligrams per day to 40 milligrams per day. The other 18,762 took placebo or an equivalently small dose of folic acid. Trials continued for a median (midpoint) of five years.
Among the 37,485 participants, 9,326 had a major vascular event during the treatment period, 3,010 developed cancer and 5,125 died. Overall, there was a 25 percent reduction in homocysteine levels associated with active folic acid supplementation. However, those who took folic acid were no less likely to have a major heart or blood vessel event than those who took placebo (4,670 or 24.9 percent of first events occurred in those taking folic acid, compared with 4,656 or 24.8 percent in the placebo group).
In addition, there was no significant difference between folic acid and placebo groups in the number of patients experiencing major coronary events (2,019 or 11.4 percent vs. 1,971 or 11.1 percent); stroke (747 or 4.2 percent vs. 781 or 4.4 percent); new cases of cancer (1,541 or 8.7 percent vs. 1,469 or 8.2 percent) or death (2,578 or 13.8 percent vs. 2.547 or 13.6 percent).
"The doses of folic acid used in all the trials included in this meta-analysis exceeded those required for near-maximal reduction in homocysteine levels," the authors write. "The randomized trials in the present meta-analysis found no evidence of benefit with treatment continued for more than five years. Although some benefit might emerge with even longer treatment and follow-up, the trial results give no reason to expect this (particularly because cardiovascular benefits tend to emerge within just a few years with other cardioprotective treatments, such as antihypertensives or statins)."
"One-third of adults in the United States and one-quarter of those in the United Kingdom report taking daily multivitamin supplements containing folic acid," they conclude. All doses in the trials were greater than those required in the United States, where foods are fortified with folic acid to prevent neural tube birth defects. "Although the lack of any other benefits is disappointing (albeit fairly definitive), the lack of any significant adverse effects on vascular events, cancer incidence, cancer mortality and overall mortality provides reassurance about the safety of population-wide folic acid fortification."
###
(Arch Intern Med. 2010;170[18]:1622-1630. Available pre-embargo to the media at www.jamamedia.org.)
Editor's Note: Sources of funding for the individual trials are described in their separate publications. The Clinical Trial Service Unit and Epidemiological Studies Unit, where the BVTT Secretariat is located, receives funding from the British Heart Foundation, U.K. Medical Research Council and Cancer Research UK. Support for this project was also provided by a grant from the U.K. Food Standards Agency. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.
END
For patients with blockages in the carotid artery that supplies blood to the brain, carotid artery stenting (a non-surgical treatment) appears to be associated with an increased risk of both short- and long-term adverse outcomes when compared with surgical treatment (carotid endarterectomy), according to a meta-analysis of previously published studies that was posted online today and will appear in the February 2011 print issue of Archives of Neurology, one of the JAMA/Archives journals.
"Carotid artery stenting has emerged as an alternative to carotid endarterectomy ...
Insulin resistance, a condition in which insulin produced by the body becomes less effective in reducing blood glucose levels, appears to be associated with an increased risk of stroke in individuals without diabetes, according to a report in the October issue of Archives of Neurology, one of the JAMA/Archives journals.
Insulin resistance originates from several factors, including genetics, a sedentary lifestyle and obesity, according to background information in the article. The condition contributes significantly to the risk of cardiovascular disease, but whether it ...
The number of Medicare recipients undergoing treatment for retinal conditions nearly doubled between 1997 and 2007, with significant shifts in the types of procedures most commonly performed, according to a report in the October issue of Archives of Ophthalmology, one of the JAMA/Archives journals.
"Retinal disease is highly prevalent among older individuals, and both age-related macular degeneration (AMD) and diabetic retinopathy account for more than half the irreversible blindness in older Americans. The prevalence of both macular degeneration and diabetic retinopathy ...
Newer treatments for age-related macular degeneration (AMD)—including an intravitreous (into the eye) injection of a chemotherapy drug and use of a related compound approved for use against the eye disease—do not appear to be associated with an increased risk of cardiovascular complications or death when compared with existing therapies, according to a report in the October issue of Archives of Ophthalmology, one of the JAMA/Archives journals.
"More than 1.5 million older Americans have age-related macular degeneration, the most common cause of irreversible vision loss ...
The Financial Markets Group at the London School of Economics carried out the research. It developed a life-cycle model to investigate how prices of housing (purchasing and renting), the overall economy and wealth distribution react to changes in technology and financial conditions.
There were a number of conclusions from the investigation, including:
stricter limitations on land development result in less residential building, which tends to push up rental and purchase prices;
availability of land for residential development is more important than availability of capital ...
Adding topotecan to carboplatin plus paclitaxel, the standard treatment for ovarian cancer, does not improve progression-free survival in patients and leads to greater toxicity, according to a study published online October 11 in the Journal of the National Cancer Institute.
Cisplatin plus paclitaxel, and carboplatin plus paclitaxel, are the most widely accepted first-line regimens for advanced epithelial ovarian cancer. Still, most women relapse and die from their disease. One possible solution is to add a third agent, such as topotecan, which has activity in the treatment ...
INDIANAPOLIS – Twenty-two physical symptoms associated with cancer – symptoms often unrecognized and undertreated – are prevalent in all types of cancers regardless of whether the patient is newly diagnosed, undergoing treatment or is a cancer survivor, according to researchers from the Regenstrief Institute and the Indiana University schools of medicine and nursing.
Common symptoms include fatigue, pain, weakness, appetite loss, dry mouth, constipation, insomnia and nausea. These physical symptoms are associated with substantial functional impairment, disability and ...
CAMBRIDGE, Mass. -- Much as an anthropologist can study populations of people to learn about their physical attributes, their environs and social structures, some marine microbiologists read the genome of microbes to glean information about the microbes themselves, their environments and lifestyles.
Using a relatively new methodology called comparative population genomics, these scientists compare the entire genomes of different populations of the same microbe to see which genes are "housekeeping" or core genes essential to all populations and which are population-specific. ...
Comprehensive new guidelines from the Osteoporosis Canada aimed at preventing fragility fractures in women and men over the age of 50 are published in CMAJ (Canadian Medical Association Journal) (pre-embargo link only) http://www.cmaj.ca/embargo/cmaj100771.pdf.
"Fragility fractures, the consequence of osteoporosis, are responsible for excess mortality, morbidity, chronic pain, institutionalization and economic costs," writes Dr. Alexandra Papaioannou, McMaster University and Hamilton Health Sciences with coauthors. "They represent 80% of all fractures in menopausal women ...
Hospital patients admitted with malnutrition or who don't eat for several days are at greater risk of a prolonged hospital stay, according to a study published in CMAJ (Canadian Medical Association Journal) (pre-embargo link only) http://www.cmaj.ca/embargo/cmaj091977.pdf.
The study, by Italian researchers, involved 1274 adults admitted to hospital for medical or surgical treatment. Patients who were bedridden, admitted for same-day surgery or procedure, or admitted for palliative care were excluded. Fifty-two patients died in hospital and 149 patients stayed less than ...
